Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 39223720.
- Also identified by DOI 10.1093/cid/ciae444 and PMC identifier 11848264.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
Medical subject headings
- Arthritis, Rheumatoid
- Inflammatory Bowel Diseases
- Invasive Fungal Infections
- Tumor Necrosis Factor-alpha